74385-37-8

Basic information

• Product Name: Methyl 4-fluoro-3-Methoxybenzoate
• Synonyms: Methyl 4-fluoro-3-Methoxybenzoate
• CAS NO: 74385-37-8
• Molecular Formula: C₉H₉FO₃
• Molecular Weight: 184.1643632
• Mol File: 74385-37-8.mol

Chemical Properties

• Melting Point: 40 °C(Solv: ethanol (64-17-5))
• Boiling Point: 250.5°C at 760 mmHg
• Flash Point: 102.2°C
• Appearance: /
• Density: 1.184g/cm³
• Vapor Pressure: 0.0216mmHg at 25°C
• Refractive Index: 1.486
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 4-fluoro-3-Methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-fluoro-3-Methoxybenzoate(74385-37-8)
• EPA Substance Registry System: Methyl 4-fluoro-3-Methoxybenzoate(74385-37-8)

Safety Data

• Hazardous Substances Data: 74385-37-8(Hazardous Substances Data)

Usage

Uses

Used in Perfumery and Fragrance Industry:
Methyl 4-fluoro-3-methoxybenzoate is used as a flavoring and fragrance agent for its sweet, fruity odor, enhancing the scent profiles of various perfumes and fragrances.
Used in Cosmetics and Personal Care Products Industry:
Methyl 4-fluoro-3-methoxybenzoate is used as a key ingredient in cosmetics and personal care products, contributing to their pleasant scent and improving consumer experience.
Used in Pharmaceutical Industry:
Methyl 4-fluoro-3-methoxybenzoate is used as a potential active pharmaceutical ingredient for the development of anti-inflammatory and anti-microbial drugs, leveraging its therapeutic properties to address various health conditions.

InChI:InChI=1/C9H9FO3/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5H,1-2H3

Upstream product

• 51446-31-2 4-fluoro-3-hydroxybenzoic acid 
• 74-88-4 methyl iodide 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 67-56-1 methanol 
• 82846-18-2 4?fluoro-3-methoxybenzoic acid 

Downstream Products

• 159768-50-0 methyl 4-fluoro-5-methoxy-2-nitrobenzoate 
• 162012-60-4 4-(3-chloro-4-fluoroanilino)-6-methoxy-7-fluoroquinazoline 
• 159768-51-1 2-amino-4-fluoro-5-methoxybenzoic acid methyl ester 
• 159768-48-6 4-chloro-7-fluoro-6-methoxyquinazoline 
• 869475-52-5 7-fluoro-6-methoxyquinazolin-4-ol 
• 247034-71-5 tert-butyl (2S)-benzenesulfonylamino-3-[3-methoxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionate 
• 247034-74-8 (2S)-benzenesulfonylamino-3-[3-hydroxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoylamino]propionic acid 
• 247035-46-7 3-methoxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoic acid 
• 247035-45-6 methyl 3-methoxy-4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 
• 247035-44-5 methyl 4-{4-(methanesulfonyloxy)piperidin-1-yl}-3-methoxybenzoate 
• 247035-43-4 4-(4-azido-piperidin-1-yl)-3-methoxy-benzoic acid methyl ester 
• 568584-57-6 methyl 4-(4-aminopiperidin-1-yl)-3-methoxybenzoate 
• 1370447-83-8 4-bromo-3-methyl-benzoic acid hydrazide 
• 1269834-31-2 (4-(1H-benzo[d]imidazol-1-yl)-3-methoxyphenyl)carboxylic acid methyl ester 

Relevant articles and documents

Pyrazole derivative for FGFR inhibitor and preparation method of pyrazole derivative

The invention provides a pyrazole derivative for an FGFR inhibitor and a preparation method of the pyrazole derivative. The invention specifically relates to an amide pyrazole compound serving as an FGFR irreversible inhibitor, and a preparation method and application thereof. The present invention provides a compound as shown in Formula I, or a pharmaceutically acceptable salt, or solvate, isotope substitute, prodrug, or metabolite thereof. The compound as shown in general formula I have FGFR inhibitory activity, and is capable of preventing or treating disorders associated with FGFR activityor expression, preferably such as cancer.

Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors

The synergistic effect of dual inhibition of serine/threonine protein kinases that are involved in the same signalling pathway of the diseases can exert superior biological benefits for treatment of these diseases. In the present work, a new series of (imidazol-5-yl)pyrimidine was designed and synthesized as dual inhibitors of BRAFV600E and p38α kinases which are considered as key regulators in mitogen-activated protein kinase (MAPK) signalling pathway. The target compounds were evaluated for dual kinase inhibitory activity. The tested compounds exhibited nanomolar scale IC50 values against BRAFV600E and low to sub-micromolar IC50 range against p38α. Compound 20h was identified as the most potent dual BRAFV600E/p38α inhibitor with IC50 values of 2.49 and 85 nM, respectively. Further deep investigation revealed that compound 20h possesses inhibitory activity of TNF-α production in lipopolysaccharide-induced RAW 264.7 macrophages with IC50 value of 96.3 nM. Additionally, the target compounds efficiently frustrated the proliferation of LOX-IMVI melanoma cell line. Compound 20h showed a satisfactory antiproliferative activity with IC50 value of 13 μM, while, compound 18f exhibited the highest cytotoxicity potency with IC50 value of 0.9 μM. Compound 18f is 11.11-fold more selective toward LOX-IMVI melanoma cells than IOSE-80PC normal cells. The newly reported compounds represent therapeutically promising candidates for further development of BRAFV600E/p38α inhibitors in an attempt to overcome the acquired resistance of BRAF mutant melanoma.

BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS

Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R 4, Y1, Y2, n and p are as defined herein.

A 1 substituted benzimidazole derivatives and the preparation method

The invention discloses a 1 substituted benzimidazole derivatives (4 - (1 H - benzo [d] imidazol - 1 - yl) - 3 - methoxyphenyl) preparation of method, in order to 4 - fluoro - 3 - methoxybenzoic acid as the starting material, through esterification, conde

Pyrazolo [3,4 - the b] pyridine and [...] composition preparation method and use of (by machine translation)

The present invention provides a pyrazolo [3,4 - the b] pyridine and [...] compound of preparation and use, in particular, the present invention provides a following formula (I) compounds are shown, wherein the definition of each group as described in the specification. The compounds of the invention has excellent tyrosine kinase inhibiting activity, so can be used for preparing a series of treating diseases associated with the tyrosine kinase activity of the drug. (by machine translation)

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocycle derivative having a superior amyloid β production inhibitory activity and/or a superior γ-secretase modulation activity, and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

A scalable synthesis of MN-447, an antagonist for integrins αvβ3 and αIIbβ 3

(2S)-Benzeneslfonylamino-3-[3-methoxy-4-{4-(1,4,5,6-tetrahydropyrimidin-2- ylamino)piperidin-1-yl}benzoylamino]propionic acid, MN-447, is a potent antagonist of the integrins αvβ33 and αIIbβ3 Herein, we report a novel synthetic protocol that produces MN-447 in an overall yield of 45%. This protocol, when compared with the original synthetic route for MN-447, is more cost-effective, requires fewer steps, does not require chromatographic purification of intermediates and MN-447, and increases the overall yield by 35%. This report focuses on the synthetic strategies that were developed for this protocol. Now, the large quantities of MN-447 that are needed for preclinical and toxicological studies can be readily obtained.

Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core

The facile preparation of 4-(3-chloro-4-fluoroanilino)-6-alkoxy-7- aminoquinazolines from their corresponding 7-triflate and 7-fluoro precursors are highlighted.

Pyrimido compounds having antiproliferative activity

Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR and FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.